Welcome to our dedicated page for Pasithea Therapeutics SEC filings (Ticker: ktta), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Pasithea Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Pasithea Therapeutics's regulatory disclosures and financial reporting.
Pasithea Therapeutics Corp. reports Coastlands-affiliated filers hold 2,394,765 shares, representing
The filing is submitted jointly by Coastlands Capital entities and Matthew D. Perry, who is identified as a control person; each reporting person disclaims membership in a group and disclaims beneficial ownership except to the extent of pecuniary interest.
Pasithea Therapeutics Corp. received a notice from Nasdaq on February 20, 2026 stating that its common stock no longer meets the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.
The company has 180 calendar days, until August 19, 2026, to regain compliance by having its stock close at or above $1.00 per share for at least ten consecutive business days. If it meets other listing standards, it may qualify for an additional 180-day period and could use actions such as a reverse stock split to cure the deficiency.
If compliance is not regained, Nasdaq staff may move to delist the shares, though the company would have the right to appeal. The company plans to monitor its share price and evaluate options, and states that this notice does not affect its business operations or SEC reporting.
Pasithea Therapeutics Corp. received an updated ownership report from institutional investors CVI Investments, Inc. and Heights Capital Management, Inc. The Reporting Persons state beneficial ownership of 899,994 shares of Pasithea common stock, representing 3.8% of the outstanding shares as of the referenced date.
The position consists of shares issuable upon exercise of warrants, which are subject to a 9.99% beneficial ownership limitation that caps how many shares can be acquired at any time. Pasithea’s definitive proxy indicates 23,091,062 shares of common stock were outstanding as of December 22, 2025, providing context for the reported 3.8% stake.
CVI Investments, Inc. is organized in the Cayman Islands and Heights Capital Management, Inc. in Delaware. Heights acts as investment manager to CVI and may exercise voting and dispositive power over the reported shares, while both parties disclaim beneficial ownership beyond their economic interest.
Pasithea Therapeutics Corp. reported ownership update from Squadron entities. Squadron Master Fund LP, its adviser Squadron Capital Management LLC, and principals Matthew Sesterhenn and William Blank report beneficial ownership of 2,329,749 shares of Pasithea common stock, including 2,100,000 shares and 229,749 shares issuable upon exercise of warrants.
These holdings represent approximately 9.99% of Pasithea’s common stock, based on 23,091,062 shares outstanding as of December 22, 2025 plus the warrant shares. The reporting persons share voting and dispositive power over all reported shares, state that the position is held in the ordinary course of business, and expressly disclaim beneficial ownership beyond what may be imputed under SEC rules.
Ameriprise Financial, Inc. and Columbia Management Investment Advisers, LLC filed a Schedule 13G reporting beneficial ownership of 1,930,128 shares of Pasithea Therapeutics Corp. common stock, equal to 8.4% of the class as of 12/31/2025.
Both entities report zero sole voting or dispositive power and shared voting and dispositive power over all reported shares. They state the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Pasithea Therapeutics.
Adage Capital Management, L.P. and related reporting persons report a 2,329,749-share beneficial stake, or 9.99% of Pasithea Therapeutics Corp. common stock. This total includes 229,749 shares issuable upon exercise of warrants held by Adage Capital Partners, L.P.
The stake, tied to an event date of December 31, 2025, is reported as being held in the ordinary course of business and not for the purpose of changing or influencing control of Pasithea. Voting and dispositive power over all reported shares is shared among the reporting persons.
Pasithea Therapeutics Corp. held a special stockholder meeting where investors approved two major share-related changes. Stockholders first approved a certificate amendment increasing authorized common stock from 100,000,000 to 500,000,000 shares, expanding the company’s capacity to issue new equity in the future.
They also approved an amendment to the 2023 Stock Incentive Plan, raising the shares authorized for issuance under the plan by 11,985,779 shares to a new total of 14,000,000 shares. Of 23,091,062 shares outstanding and entitled to vote, 16,746,261 were represented, and both proposals passed by majority vote.
Pasithea Therapeutics Corp. has regained compliance with Nasdaq’s minimum $1.00 bid price requirement for its common stock.
The company had previously received a notice on June 23, 2025 that its shares were below the $1.00 minimum bid price set by Nasdaq Listing Rule 5550(a)(2) and was given until December 22, 2025 to cure the deficiency. On December 12, 2025, Nasdaq informed Pasithea that the stock had maintained a closing bid at or above $1.00 per share for a sufficient number of consecutive business days and confirmed that the matter is now closed.